Frameshift

What Frameshift does

Frameshift Innovation is a life sciences company builder and venture accelerator headquartered in Austin, Texas. Rather than commercializing a single product, the firm operates as a portfolio-based holding company that founds, incubates, and advances therapeutic and diagnostic companies from concept to clinical stage. Frameshift works both internally and with external investigators, scientists, entrepreneurs, and investors to source and develop programs primarily targeting human health applications. The organization is structured as Frameshift Management, Inc., a private corporation with 1-10 employees at the parent level, and generates returns through equity ownership in portfolio companies rather than direct product sales.

The portfolio comprises six distinct subsidiaries spanning multiple therapeutic modalities and technology layers. Aperta Biosciences develops ocular surface disease treatments, with lead asset APT-001 (spinosad) in a Phase 2 clinical trial for chronic blepharitis. Epiclone focuses on high-precision cancer immunotherapies. Foundation Bio generates biochemical data intended to power next-generation foundation models. Angstrom Bio develops amplicon sequencing technologies for rare variant detection in infectious disease and oncology. Affigen builds personalized monoclonal antibodies for patient-specific, tumor-specific targets in hematological malignancies. Tropicalis Pharmaceuticals targets neglected tropical diseases and was formed as a partnership with Clarus Ventures (now Blackstone Life Sciences). Five subsidiaries are wholly owned, while Tropicalis is structured as a jointly controlled interest.

Frameshift maintains a multi-regional operational footprint spanning Austin (corporate headquarters at 1108 Lavaca St., Ste 110-329), the San Francisco Bay Area, and Central America. The company positions itself as a lean holding entity that supplies infrastructure, capital, and domain expertise to portfolio companies while leveraging external collaborators and co-investors for execution. Customer-facing revenue mechanics at the parent level are not disclosed, and the franchise economics depend on equity appreciation, licensing, or eventual monetization events across the subsidiary portfolio.

Name

Frameshift

Legal name

Frameshift Management, Inc.

Website

https://frameshift.co

Company type

Private

Founded year

2016

Operating status

Operating

Headcount range

1–10 employees

Short description

Frameshift Innovation is an Austin-based life sciences company builder that founds and develops therapeutic and diagnostic portfolio companies. It operates six subsidiaries spanning ocular disease treatments, cancer immunotherapies, biochemical data for AI models, sequencing diagnostics, personalized monoclonal antibodies, and neglected tropical disease therapeutics.

Ownership category

akta.pro rank

Product category

Life Sciences Venture Building

NAICS

Research and Development in Biotechnology (except Nanobiotechnology) (541714), Research and Development in the Physical, Engineering, and Life Sciences (54171), Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology) (541715)

SIC

Services-Commercial Physical & Biological Research (8731)

akta.pro primary industry

Accelerators & Incubators (Investor-Operated) (FSANAAAM)

Keywords

• Life sciences venture building
• Therapeutics incubation
• Diagnostics development
• Biotech portfolio companies
• Clinical program acceleration

Headquarters

HQ city

Austin

HQ country

United States

HQ region

North America

Offices3 records

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Operations, Technology or R&D, Marketing or Sales, Infrastructure

Core offering

Frameshift Innovation is a life sciences company builder that starts and develops therapeutic and diagnostic programs from concept to clinic. It operates both internally and alongside external investigators, scientists, entrepreneurs, and investors, founding and advancing a portfolio of subsidiary companies (Aperta Biosciences, Epiclone, Foundation Bio, Angstrom Bio, Affigen, and Tropicalis Pharmaceuticals) targeting human health.

Product overview

Frameshift Innovation is a life sciences company builder and accelerator that starts and develops therapeutic and diagnostic programs from concept to clinic. Rather than offering a single unified product or platform, Frameshift operates as a portfolio-based holding company that has founded and built six distinct subsidiary companies: Aperta Biosciences (ocular surface disease treatments, including APT-001 in Phase 2 for chronic blepharitis), Epiclone (cancer immunotherapies), Foundation Bio (biochemical data for AI foundation models), Angstrom Bio (amplicon sequencing for rare variant detection), Affigen (personalized monoclonal antibodies for hematological malignancies), and Tropicalis Pharmaceuticals (treatments for neglected tropical diseases). The portfolio spans therapeutic programs, diagnostic technologies, and data infrastructure for the life sciences industry.

Differentiator

Problem solved

Functional benefit

Products and services

• Aperta Biosciences Wholly owned subsidiary developing novel treatments for ocular surface diseases; lead program APT-001 (spinosad) is in a Phase 2 clinical trial for chronic blepharitis. Targeted at patients with ocular surface disease and the ophthalmology clinical community.
• Epiclone Wholly owned subsidiary developing high-precision immunotherapies for cancer applications. Targeted at oncology researchers, clinicians, and patients with cancer.
• Foundation Bio Wholly owned subsidiary generating the biochemical data needed to power the next generation of AI foundation models. Targeted at AI and life-sciences research teams building foundation models that require high-quality biochemical training data.
• Angstrom Bio Wholly owned subsidiary developing amplicon sequencing technologies for rapid and cost-effective detection of rare variants in infectious disease and oncology. Targeted at clinical and research laboratories requiring rare-variant detection.
• Affigen Wholly owned subsidiary developing personalized monoclonal antibodies from discovery through dosing against patient-specific, tumor-specific targets in hematological malignancies. Targeted at clinicians and patients with hematological cancers.
• Tropicalis Pharmaceuticals Joint-venture portfolio company formed with Clarus Ventures (now Blackstone Life Sciences) to develop safe and effective treatments for Neglected Tropical Diseases. Targeted at global-health populations and partners addressing underserved disease areas.

Segments1 record

Ideal customer profiles1 record

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Recent moves5 records

Expansion highlights4 records

Direct peers

• BioMotiv: BioMotiv operates as a therapeutic accelerator, identifying and advancing promising academic and early-stage programs into operating companies. Its mission-driven, multi-program structure parallels Frameshift's incubator-style approach.
• Roivant Sciences: Roivant Sciences operates a comparable company-builder model in life sciences, incubating and advancing multiple therapeutic subsidiary companies (Vants) and retaining equity across a diversified portfolio — directly analogous to how Frameshift operates Aperta, Epiclone, Affigen and others.
• PureTech Health: PureTech Health founded and operates multiple therapeutic and platform subsidiaries, advancing programs from concept through clinical development with a centralized R&D and capital-allocation model — closely mirroring Frameshift's portfolio approach.
• BridgeBio Pharma: BridgeBio develops multiple therapeutic programs in parallel through a hub-and-spoke operating model, with subsidiaries advancing assets across genetic and rare diseases. The parallel-portfolio structure and emphasis on clinical-stage execution make it one of Frameshift's closest comparable peers.
• Accelerator Life Science Partners: Accelerator Life Science Partners is a dedicated biotech accelerator that invests in and operates early-stage therapeutic companies — a more specialized, smaller-scale version of Frameshift's life sciences company-builder model.

Broad incumbents

• ARCH Venture Partners: ARCH Venture Partners is a leading early-stage life sciences investor that frequently co-creates biotech companies alongside scientific founders. Its investor-operated company-creation approach makes it a relevant incumbent comparator for Frameshift's model.
• Atlas Venture: Atlas Venture is a long-established early-stage life sciences venture firm that both funds and actively builds biotech companies from inception. Its company-creation model overlaps meaningfully with Frameshift's approach, though Atlas operates with significantly more capital.
• Deerfield Management: Deerfield Management is a large healthcare investment firm that both funds and helps build life sciences companies across therapeutics, diagnostics, and health tech. Its portfolio-building and operational support model overlaps with Frameshift's company-builder approach at greater scale.
• Flagship Pioneering: Flagship Pioneering creates and operates breakthrough life sciences companies (including Moderna) through an innovation foundry model. It is a much larger, established version of the biotech company-builder concept Frameshift pursues.

Emerging players

• Inception Therapeutics: Inception Therapeutics is an emerging company builder focused on creating and developing multiple clinical-stage therapeutic ventures — a smaller-scale, more focused analog to Frameshift's multi-subsidiary platform.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks5 records

Key highlights6 records

Customer concentration

• LinkedInlinkedin.com/company/frameshift

Revenue estimate

Valuation estimate

Number of profiles

Profiles1 record

Subsidiaries6 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Frameshift